• Cat-intel
  • MedIntelliX
  • Consulting
  • Resources
  • About Us
  • News
  • Careers
  • Contact Us
  • Login
    • Request Free Sample ×
    Cancer Immunotherapy Market Research Report –Forecast till 2035 Infographic

    Kindly complete the form below to receive a free sample of this Report

    Leading companies partner with us for data-driven Insights

    clients tt-cursor
    Hero Background

    Cancer Immunotherapy Market

    ID: MRFR/HC/0149-HCR
    200 Pages
    Rahul Gotadki
    October 2025

    Cancer Immunotherapy Market Size, Growth Research Report By Therapy Type (Monoclonal Antibodies, Check Point Inhibitors, Cancer Vaccines, Therapeutic T-Cells, Oncolytic Virus Therapy), By Cancer Type (Breast Cancer, Lung Cancer, Colorectal Cancer, Prostate Cancer, Melanoma), By End User (Hospitals, Cancer Research Institutes, Diagnostics Labs), By Route of Administration (Intravenous, Subcutaneous, Intramuscular) and By Regional (North America, Europe, South America, Asia Pacific, Middle East and Africa) – Competitor Industry Analysis and Tr...

    Share:
    Download PDF ×

    We do not share your information with anyone. However, we may send you emails based on your report interest from time to time. You may contact us at any time to opt-out.

    Cancer Immunotherapy Market Infographic
    Purchase Options
    Compare License
    Summary Table of Contents Segmentation Download PDF

    Cancer Immunotherapy Market Summary

    As per MRFR analysis, the Cancer Immunotherapy Market was estimated at 73.7 USD Billion in 2024. The Cancer Immunotherapy industry is projected to grow from 77.38 USD Billion in 2025 to 125.93 USD Billion by 2035, exhibiting a compound annual growth rate (CAGR) of 4.99 during the forecast period 2025 - 2035.

    Key Market Trends & Highlights

    The Cancer Immunotherapy Market is experiencing robust growth driven by innovative therapies and increasing demand for personalized treatment options.

    • The rise of personalized medicine is reshaping treatment paradigms, particularly in North America, which remains the largest market.
    • Combination therapies are gaining traction, especially in the breast cancer segment, which continues to dominate the market.
    • Investment in research and development is surging, particularly in the Asia-Pacific region, recognized as the fastest-growing market.
    • The growing prevalence of cancer and advancements in technology are key drivers propelling the market forward.

    Market Size & Forecast

    2024 Market Size 73.7 (USD Billion)
    2035 Market Size 125.93 (USD Billion)
    CAGR (2025 - 2035) 4.99%

    Major Players

    Bristol-Myers Squibb (US), Merck & Co. (US), Roche (CH), Novartis (CH), Amgen (US), AstraZeneca (GB), Gilead Sciences (US), Regeneron Pharmaceuticals (US), Eli Lilly and Company (US)

    Cancer Immunotherapy Market Trends

    The Cancer Immunotherapy Market is currently experiencing a transformative phase, characterized by rapid advancements in treatment modalities and a growing understanding of the immune system's role in combating cancer. This market appears to be driven by an increasing prevalence of various cancer types, alongside a rising demand for more effective and personalized treatment options. Pharmaceutical companies are investing heavily in research and development, leading to the introduction of novel therapies that harness the body's immune response. Furthermore, collaborations between academic institutions and industry players seem to be fostering innovation, potentially accelerating the pace of new product development. In addition, regulatory bodies are adapting to the evolving landscape of cancer treatments, which may facilitate faster approvals for promising therapies. The Cancer Immunotherapy Market is also witnessing a shift towards combination therapies, where immunotherapeutic agents are used alongside traditional treatments, such as chemotherapy and radiation. This approach could enhance treatment efficacy and improve patient outcomes. Overall, the market appears poised for substantial growth, driven by scientific advancements and a commitment to improving cancer care.

    Rise of Personalized Medicine

    The Cancer Immunotherapy Market is increasingly leaning towards personalized medicine, where treatments are tailored to individual patient profiles. This trend suggests a shift from one-size-fits-all approaches to more targeted therapies, potentially enhancing treatment effectiveness and minimizing adverse effects.

    Combination Therapies

    There is a notable trend towards the use of combination therapies in the Cancer Immunotherapy Market. By integrating immunotherapy with traditional treatment modalities, such as chemotherapy and radiation, clinicians may achieve improved patient outcomes and greater therapeutic efficacy.

    Increased Investment in Research and Development

    Investment in research and development within the Cancer Immunotherapy Market appears to be on the rise. Pharmaceutical companies are allocating substantial resources to explore innovative treatment options, which may lead to the discovery of new therapies and enhance the overall landscape of cancer treatment.

    The ongoing advancements in cancer immunotherapy are reshaping treatment paradigms, offering new hope for patients through innovative therapies that harness the body's immune system to combat malignancies.

    National Cancer Institute

    Cancer Immunotherapy Market Drivers

    Advancements in Technology

    Technological innovations play a crucial role in shaping the Cancer Immunotherapy Market. The emergence of advanced techniques such as CRISPR gene editing, next-generation sequencing, and artificial intelligence in drug discovery has revolutionized the development of immunotherapeutic agents. These technologies enable researchers to identify novel targets and develop personalized therapies tailored to individual patients. As a result, the Cancer Immunotherapy Market is witnessing a surge in the introduction of new products and treatment modalities, enhancing the overall efficacy of cancer treatments. The integration of technology into immunotherapy development is expected to drive market growth and expand treatment options for patients.

    Growing Prevalence of Cancer

    The increasing incidence of cancer worldwide is a primary driver for the Cancer Immunotherapy Market. According to recent statistics, cancer cases are projected to rise significantly, with estimates suggesting that by 2040, there could be over 27 million new cancer cases annually. This alarming trend necessitates the development of innovative treatment options, including immunotherapy, which harnesses the body's immune system to combat cancer. As healthcare systems strive to address this growing burden, the Cancer Immunotherapy Market is likely to experience substantial growth, driven by the demand for effective therapies that can improve patient outcomes and survival rates.

    Rising Awareness and Education

    The increasing awareness and education surrounding cancer immunotherapy are pivotal drivers for the Cancer Immunotherapy Market. As healthcare professionals and patients become more informed about the benefits and potential of immunotherapy, the demand for these treatments is expected to rise. Educational initiatives, conferences, and patient advocacy groups play a vital role in disseminating information about immunotherapy options. This heightened awareness can lead to more patients seeking immunotherapy as a viable treatment option, thereby expanding the market. The Cancer Immunotherapy Market is likely to benefit from this trend, as more individuals become aware of the advancements in cancer treatment.

    Regulatory Support and Approvals

    Regulatory bodies are increasingly supportive of cancer immunotherapy, which significantly impacts the Cancer Immunotherapy Market. Recent years have seen a rise in the number of approvals for immunotherapeutic agents, with agencies like the FDA and EMA expediting the review process for promising therapies. This regulatory environment fosters innovation and encourages pharmaceutical companies to invest in research and development of new immunotherapies. The approval of novel agents not only enhances treatment options for patients but also stimulates market growth, as more therapies become available to address various cancer types. The supportive regulatory landscape is likely to continue driving the Cancer Immunotherapy Market forward.

    Investment in Healthcare Infrastructure

    Investment in healthcare infrastructure is a significant driver for the Cancer Immunotherapy Market. Governments and private entities are increasingly allocating resources to enhance healthcare systems, particularly in oncology. This investment includes the establishment of specialized cancer treatment centers, research facilities, and access to cutting-edge technologies. As healthcare infrastructure improves, the availability and accessibility of cancer immunotherapy treatments are expected to increase. Enhanced infrastructure not only supports the delivery of immunotherapy but also facilitates clinical trials and research, further propelling the Cancer Immunotherapy Market. The ongoing investment in healthcare is likely to create a favorable environment for the growth of immunotherapy.

    Market Segment Insights

    By Type: Monoclonal Antibodies (Largest) vs. Check Point Inhibitors (Fastest-Growing)

    In the Cancer Immunotherapy Market, Monoclonal Antibodies dominate the landscape, holding the largest market share due to their widespread acceptance and proven efficacy in treating various cancer types. These therapies work by targeting specific antigens on cancer cells, leading to effective immune responses. Check Point Inhibitors, while currently not the largest, are rapidly gaining traction and are recognized as the fastest-growing segment, owing to their ability to enhance the immune system's capacity to fight cancer cells. The growth of Check Point Inhibitors is largely driven by their effectiveness in various malignancies, including melanoma and lung cancer, and their potential to be combined with other treatment modalities for enhanced efficacy. The increased understanding of immune checkpoint mechanisms is promoting research and development in this area, paving the way for innovative therapies. Furthermore, the rising incidence of cancer worldwide and the burgeoning investment in immunotherapy research contribute to the promising future of these segments in the oncology landscape.

    Monoclonal Antibodies (Dominant) vs. Therapeutic T-Cells (Emerging)

    Monoclonal Antibodies are currently the dominant player in the Cancer Immunotherapy Market due to their extensive clinical application and proven success across multiple cancer types. Administered as part of combination therapies or as standalone treatments, these antibodies provide personalized and targeted treatment options that significantly improve patient outcomes. In contrast, Therapeutic T-Cells represent an emerging segment, showcasing innovative potential through engineered T-cell therapies, such as CAR T-cell therapy. These therapeutic options are designed to enhance the immune response against tumor cells, offering hope for difficult-to-treat cancers. As research advances and clinical trials expand, Therapeutic T-Cells have the potential to grow significantly, driven by their successful results and increasing acceptability among healthcare providers.

    By Cancer Type: Breast Cancer (Largest) vs. Melanoma (Fastest-Growing)

    In the Cancer Immunotherapy Market, Breast Cancer holds the largest market share, driven by the ongoing advancements in targeted therapies and a growing patient population. As awareness and screening programs improve, the incidence rates of breast cancer remain substantial, ensuring that this segment continues to dominate in terms of revenue generation. Conversely, Melanoma is recognized as the fastest-growing segment due to increasing environmental factors like UV exposure and the rising incidence of skin cancers. This growth is further fueled by innovations in immunotherapy treatments specifically targeting tumor microenvironments and enhancing immune responses.

    Breast Cancer (Dominant) vs. Melanoma (Emerging)

    Breast Cancer immunotherapy has established itself as the dominant force within the Cancer Immunotherapy Market, thanks to the extensive research and development focusing on monoclonal antibodies and checkpoint inhibitors. Its established treatment options have created a robust pipeline, with healthcare providers increasingly opting for tailored immunotherapeutic approaches. On the other hand, Melanoma is emerging rapidly, reflecting a shift in focus towards personalized medicine and novel therapeutic platforms. The development of innovative therapies aimed at specific genetic markers has attracted significant investment, contributing to a surge in the availability of treatment options and clinical trials. This dynamic landscape showcases the potential for both segments to evolve and influence the future of cancer treatment.

    By End User: Hospitals (Largest) vs. Cancer Research Institutes (Fastest-Growing)

    In the Cancer Immunotherapy Market, the end-user segment showcases a prominent distribution between hospitals, cancer research institutes, and diagnostics labs. Hospitals represent the largest share due to their comprehensive facilities and resources for patient care, serving as the primary setting for immunotherapy treatments. Meanwhile, cancer research institutes are rapidly gaining traction as innovative centers that develop and test new therapies, positioning them as the fastest-growing segment within this landscape.

    Hospitals (Dominant) vs. Cancer Research Institutes (Emerging)

    Hospitals play a dominant role in the Cancer Immunotherapy Market, offering critical treatment services and housing multidisciplinary teams that manage patient care across various tumor types. Their extensive operational capabilities allow them to administer advanced immunotherapeutic agents effectively, fostering a robust treatment regimen for patients. Conversely, cancer research institutes are emerging as vital contributors focused on groundbreaking research and development of next-generation therapies. They attract significant investment and collaboration opportunities, driving an ecosystem that nurtures clinical trials and innovative treatment methodologies, further propelling their growth in the market.

    By Route of Administration: Intravenous (Largest) vs. Subcutaneous (Fastest-Growing)

    In the Cancer Immunotherapy Market, the distribution of market share among the route of administration segments shows a significant preference for intravenous (IV) delivery. The IV route stands out as the largest segment due to its rapid and effective distribution of therapeutic agents directly into the bloodstream. Subcutaneous administration is on the rise, rapidly gaining traction among healthcare providers and patients alike, due to its ease of administration and potential for self-administration. The growth trends in this segment indicate a shift towards subcutaneous approaches, primarily driven by advancements in formulation technologies and patient preference for less invasive methods. This, combined with ongoing research and development efforts, positions subcutaneous administration as the fastest-growing route in cancer immunotherapy. The IV route remains essential for complex treatments, particularly in hospital settings where immediate therapeutic effects are desired.

    Administration Route: Intravenous (Dominant) vs. Subcutaneous (Emerging)

    Intravenous administration is a dominant route in cancer immunotherapy, primarily due to its ability to ensure the complete bioavailability of drugs and the rapid onset of action, making it essential for potent treatments that require immediate impact. It is commonly used in hospital settings for patients receiving intensive therapy, often allowing for close monitoring. On the other hand, subcutaneous administration is emerging as a preferred method for many patients as it offers convenience and can facilitate at-home administration, thus improving patient compliance. The flexibility of subcutaneous delivery means it can cater to different formulations and dosage forms, which adds to its attractiveness. Overall, both segments are vital in the landscape of cancer immunotherapy, catering to diverse patient needs.

    Get more detailed insights about Cancer Immunotherapy Market
    Request Free Sample

    Regional Insights

    The Cancer Immunotherapy Market shows a diverse regional landscape, reflecting varying healthcare dynamics across the globe. North America dominates the market with a valuation of 35.1 USD Billion in 2024, projected to rise to 59.5 USD Billion by 2035, showcasing significant investment in Research and Development and advanced healthcare infrastructure.

    Europe follows with a market value of 20.5 USD Billion in 2024, expected to reach 34.0 USD billion in 2035, underscoring the importance of progressive regulatory frameworks and strong clinical research initiatives.Meanwhile, South America and Asia Pacific demonstrate notable growth potential; South America is valued at 3.5 USD Billion in 2024 and is set to grow to 6.0 USD Billion by 2035, while Asia Pacific’s market will increase from 8.3 USD Billion to 15.0 USD Billion in the same period, driven by increasing incidences of cancer and improving healthcare access.

    The Middle East and Africa, although valued at a modest 2.8 USD Billion in 2024, are anticipated to grow to 5.5 USD Billion, highlighting emerging opportunities in oncology treatment. The disparities in regional valuations reflect varied healthcare investments, patient demographics, and disease prevalence, contributing to distinct market trends and challenges in each region.

    Cancer Immunotherapy Market Regional Insights

    Source: Primary Research, Secondary Research, Market Research Future Database, and Analyst Review

    Key Players and Competitive Insights

    The Cancer Immunotherapy Market is characterized by rapid advancements in research and development, driven by the increasing prevalence of cancer and the need for innovative treatment options to enhance patient outcomes. The market is highly competitive, with several key players striving to establish themselves as leaders through a variety of strategic initiatives, such as collaborations, acquisitions, and product launches.

    Companies are focusing on developing novel therapies that leverage the body's immune system to fight cancer, resulting in a diverse range of product offerings encompassing monoclonal antibodies, immune checkpoint inhibitors, cancer vaccines, and adoptive cell therapies. Furthermore, the drive towards personalized medicine is reshaping the competitive landscape, as firms increasingly seek to tailor immunotherapeutic approaches to individual patient profiles, thereby enhancing efficacy and minimizing adverse effects. In this competitive environment, Novartis stands out due to its robust portfolio and commitment to innovation within the Cancer Immunotherapy Market.

    The company's strategic investments in research have allowed it to offer a variety of therapies that are at the forefront of immunotherapy advancements. Novartis has a well-established global presence and is recognized for its ability to leverage its extensive research and development capabilities to bring cutting-edge treatments to market.

    The company's focus on forging strategic partnerships and collaborations with leading research institutions and biotech firms further enhances its competitive edge. This enables Novartis to stay ahead in the market by not only expanding its product offerings but also ensuring access to the latest technological advancements in cancer treatment.

    The integration of diverse therapeutic options and the continued pursuit of innovative solutions underline the company's strengths in addressing specific patient needs and improving treatment outcomes across different cancer types.Regeneron Pharmaceuticals also plays a significant role in the Cancer Immunotherapy Market with a distinct focus on developing monoclonal antibodies and other biologics that target immune pathways. The company is recognized for its flagship products that harness the immune system's response to cancer and has a strategic focus on groundbreaking research and clinical trials that expand its therapeutic offerings.

    Regeneron's commitment to precision medicine and its ability to rapidly advance new discoveries into clinical applications have solidified its reputation within the industry.

    The company has explored various opportunities for mergers and acquisitions to bolster its capabilities and diversify its portfolio, further enhancing its competitive positioning. The global reach of Regeneron, combined with its innovative therapies and a dynamic approach to addressing unmet medical needs in oncology, strengthens its market presence and solidifies its place as a key player in the evolving landscape of cancer immunotherapy.

    Key Companies in the Cancer Immunotherapy Market market include

    Industry Developments

    The Cancer Immunotherapy Market has witnessed substantial growth in recent years, driven by continuous innovation and increasing investment from leading pharmaceutical companies. In September 2023, Merck reported positive data from its Phase III clinical trial evaluating Keytruda (pembrolizumab) in combination with chemotherapy for advanced non-small cell lung cancer, further solidifying its leadership in the immunotherapy space.

    Gilead Sciences, through its subsidiary Kite Pharma, continues to expand its CAR-T cell therapy portfolio. In August 2023, Gilead received expanded FDA approval for Yescarta (axicabtagene ciloleucel) in earlier lines of therapy for large B-cell lymphoma, reflecting advancements in cell-based immunotherapy.

    In May 2023, AstraZeneca announced a strategic collaboration with Scorpion Therapeutics to develop precision immuno-oncology therapies, strengthening its pipeline in tumor-specific immune modulation. Meanwhile, Pfizer continues to invest in immunotherapy through internal development and co-commercialization of Bavencio (avelumab) with Merck KGaA, primarily targeting urothelial carcinoma and Merkel cell carcinoma.

    The market has also been shaped by key regulatory events. In October 2023, the FDA granted accelerated approval to Imdelltra (tarlatamab-dlle) by Amgen, a bispecific T-cell engager for small cell lung cancer, marking a significant milestone in bispecific antibody development. Overall, the cancer immunotherapy market continues to expand, supported by growing global demand for personalized and targeted treatments, favorable regulatory pathways, and a robust pipeline of innovative immunotherapeutics addressing both solid tumors and hematologic malignancies.

    Future Outlook

    Cancer Immunotherapy Market Future Outlook

    The Cancer Immunotherapy Market is projected to grow at a 4.99% CAGR from 2024 to 2035, driven by advancements in personalized medicine, increasing R&D investments, and rising cancer prevalence.

    New opportunities lie in:

    • Development of combination therapies to enhance treatment efficacy.
    • Expansion into emerging markets with tailored immunotherapy solutions.
    • Investment in digital health technologies for patient monitoring and engagement.

    By 2035, the Cancer Immunotherapy Market is expected to achieve substantial growth and innovation.

    Market Segmentation

    Cancer Immunotherapy Market Type Outlook

    • Monoclonal Antibodies
    • Check Point Inhibitors
    • Cancer Vaccines
    • Therapeutic T-Cells
    • Oncolytic Virus Therapy

    Cancer Immunotherapy Market End User Outlook

    • Hospitals
    • Cancer Research Institutes
    • Diagnostics Labs

    Cancer Immunotherapy Market Cancer Type Outlook

    • Breast Cancer
    • Lung Cancer
    • Colorectal Cancer
    • Prostate Cancer
    • Melanoma

    Cancer Immunotherapy Market Route of Administration Outlook

    • Intravenous
    • Subcutaneous
    • Intramuscular

    Report Scope

    MARKET SIZE 202473.7(USD Billion)
    MARKET SIZE 202577.38(USD Billion)
    MARKET SIZE 2035125.93(USD Billion)
    COMPOUND ANNUAL GROWTH RATE (CAGR)4.99% (2024 - 2035)
    REPORT COVERAGERevenue Forecast, Competitive Landscape, Growth Factors, and Trends
    BASE YEAR2024
    Market Forecast Period2025 - 2035
    Historical Data2019 - 2024
    Market Forecast UnitsUSD Billion
    Key Companies ProfiledMarket analysis in progress
    Segments CoveredMarket segmentation analysis in progress
    Key Market OpportunitiesAdvancements in personalized therapies and combination treatments drive growth in the Cancer Immunotherapy Market.
    Key Market DynamicsRising demand for personalized therapies drives innovation and competition in the Cancer Immunotherapy Market.
    Countries CoveredNorth America, Europe, APAC, South America, MEA

    Market Highlights

    Author
    Rahul Gotadki
    Assistant Manager

    He holds an experience of about 7+ years in Market Research and Business Consulting, working under the spectrum of Life Sciences and Healthcare domains. Rahul conceptualizes and implements a scalable business strategy and provides strategic leadership to the clients. His expertise lies in market estimation, competitive intelligence, pipeline analysis, customer assessment, etc. In addition to the above, his other responsibility includes strategic tracking of high growth markets & advising clients on the potential areas of focus they could direct their business initiatives

    Get In Touch

    Leave a Comment

    FAQs

    What is the projected market size of the Cancer Immunotherapy Market in 2024?

    The Cancer Immunotherapy Market is expected to be valued at 70.2 USD Billion in 2024.

    What will the Cancer Immunotherapy Market be valued at by 2035?

    By 2035, the Cancer Immunotherapy Market is projected to reach a value of 120.0 USD billion.

    What is the expected CAGR for the Cancer Immunotherapy Market from 2025 to 2035?

    The expected CAGR for the Cancer Immunotherapy Market from 2025 to 2035 is 4.99%.

    Which region is expected to dominate the Cancer Immunotherapy Market in 2024?

    North America is expected to dominate the Cancer Immunotherapy Market with a value of 35.1 USD Billion in 2024.

    What is the market size of Europe in the Cancer Immunotherapy Market for 2024?

    The market size for Europe in the Cancer Immunotherapy Market is projected to be 20.5 USD billion in 2024.

    How much is the Cancer Immunotherapy Market expected to grow in Asia Pacific by 2035?

    The Cancer Immunotherapy Market in Asia Pacific is expected to grow to 15.0 USD billion by 2035.

    What are some of the key players in the Cancer Immunotherapy Market?

    Key players in the Cancer Immunotherapy Market include Novartis, Merck, Gilead Sciences, and Bristol Myers Squibb.

    What is the market size for Monoclonal Antibodies in 2024?

    The market size for Monoclonal Antibodies in the Cancer Immunotherapy Market is valued at 25.0 USD Billion in 2024.

    How much are Check Point Inhibitors projected to be worth by 2035?

    Check Point Inhibitors are projected to be worth 28.0 USD billion in the Cancer Immunotherapy Market by 2035.

    What challenges might the Cancer Immunotherapy Market face in the coming years?

    The Cancer Immunotherapy Market may face challenges related to regulatory changes and high treatment costs as it evolves.

    Download Free Sample

    Kindly complete the form below to receive a free sample of this Report

    No regional reports available for this market.

    No country-specific reports available for this market.

    Customer Stories
    Case Study
    Chemicals and Materials
    Global Magnesium Sulfate Market – Forecast till 2027

    Compare Licence

    ×
    Features License Type
    Single User Multiuser License Enterprise User
    Price $4,950 $5,950 $7,250
    Maximum User Access Limit 1 User Upto 10 Users Unrestricted Access Throughout the Organization
    Free Customization ✓ ✓ ✓
    Direct Access to Analyst ✓ ✓ ✓
    Deliverable Format ✓ ✓ ✓
    Platform Access ✗ ✗ ✓
    Discount on Next Purchase 10% 15% 15%
    Printable Versions ✗ ✗ ✓